Track Xeris Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Xeris Pharmaceuticals, Inc. XERS · Stock Open Xeris Pharmaceuticals, Inc. in new tab

16.66 USD
P/E
115.43
EPS
-0.03
P/B
61.29
ROE
-27.11
Beta
0.84
Target Price
17.29 USD
Xeris Pharmaceuticals, Inc. logo

Xeris Pharmaceuticals, Inc.

🧾 Earnings Recap – Q1 2026

Xeris Biopharma's shares rose modestly by 2.5% following Q1 results that showed solid revenue growth driven by Recorlev's strong performance, while Gvoke’s sales were hampered by Medicare-related headwinds, tempering broader enthusiasm.

  • Total revenue grew 38% year-over-year to $83.1 million, with net product revenue up 43% to $82.5 million.
  • Recorlev revenue nearly doubled (+95%) to approximately $50 million, driven by record referrals and new patient starts, especially post-Q1 payer resets.
  • Gvoke revenue remained flat year-over-year at $20.8 million, impacted by Medicare policy and plan changes that increased out-of-pocket costs and reduced prescription fills.
  • Keveyis posted a modest 4% revenue increase to around $12 million, marking its second consecutive quarter of year-over-year growth.
  • XP-8121 remains on track for Phase III initiation later this year, leveraging existing commercial and technological capabilities.
📅
Loading chart...
Key Metrics
Earnings dateMarch 1, 2027
P/E115.43
EPS-0.03
Book Value0.27
Price to Book61.29
Debt/Equity463.40
% Insiders2.997%
Growth
Revenue Growth0.44%
Earnings Growth16.16%
Estimates
Forward P/E50.35
Forward EPS0.33
Target Mean Price17.29

DCF valuation

Model fair value for Xeris Pharmaceuticals, Inc. (XERS)
Result
Sign in to run the valuation for XERS.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
7 analysts · consensus Strong buy · mean target 17.29 USD (low 12.00, high 21.00) · as of 11 Nov 2026
Low 12.00
Mean 17.29
High 21.00
Price 16.66
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Xeris Pharmaceuticals, Inc. Logo Xeris Pharmaceuticals, Inc. Analysis (XERS)

United States Health Care Official Website Stock

Is Xeris Pharmaceuticals, Inc. a good investment? Xeris Pharmaceuticals, Inc. (XERS) is currently trading at 16.66 USD. Market analysts have a consensus price target of 17.29 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 115.43. This high multiple suggests investors have priced in significant future growth expectations.

Earnings Schedule: Xeris Pharmaceuticals, Inc. is expected to release its next earnings report on March 1, 2027. The market consensus estimate for Forward EPS is 0.33.

Investor FAQ

Does Xeris Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Xeris Pharmaceuticals, Inc.?

Xeris Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be March 1, 2027. The company currently has a trailing EPS of -0.03.

Company Profile

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Exchange Ticker
NMS (United States) XERS
FRA (Germany) 2B3.F
MUN (Germany) 2B3.MU
LSE (United Kingdom) 0A8E.L
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion